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1.Introduction 
Cholera outbreaks are reported every year in more than 50 countries worldwide, both in 
emergency and non-emergency contexts. Every year there are an estimated 3–5 million 
cholera cases, and 100,000–120,000 deaths. Case fatality rates as high as 50% have been 
reported for untreated cholera, but can be reduced to 1% with rapid and comprehensive 
treatment. During cholera epidemics the number of cases can rapidly escalate to hundreds 
of patients in need for immediate therapy, and severe cases will survive only if effectively, 
timely and safely treated.  
This chapter will review the evidence behind the treatment of cholera, providing an up to 
date description of what we know on cholera treatment from existing scientific literature. 
The review takes into consideration different aspects of cholera treatment, such as fluids, 
antibiotics, zinc, and anti-diarrhoeal agents. The types of evidence searched for this 
umbrella review includes guidelines, systematic reviews and, where needed, clinical trials. 
Systematic reviews were searched in the Cochrane Library and in MEDLINE (1966 to 2011). 
In areas of treatment for which no systematic review was retrieved, or when retrieved 
systematic reviews were over two years old, single studies were searched in the following 
databases of primary research: the Cochrane Central Register of Controlled Trials 
(CENTRAL), MEDLINE (1966 to 2011). Guidelines for cholera management were searched 
in the following databases: MEDLINE (1966 to 2011); World Health Organization (WHO); 
Center of Diseases and Control (CDC); National Institute for health and Clinical Excellence 
(NICE); National Guidelines Clearinghouse.  
1.1 When to suspect cholera 
Cholera should be suspected when a child older than 5 years or an adult develops severe 
dehydration from acute watery diarrhoea (usually with vomiting), or when any patient 
older than 2 years has acute watery diarrhoea when cholera is known to be occurring in the 
area. Younger children also develop cholera, but the illness may be difficult to distinguish 
from other causes of acute watery diarrhoea, especially rotavirus (WHO 2011). 
Cholera differs from acute diarrhoea for other causes in three ways: 
 it occurs in large epidemics that involve both children and adults; 
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 voluminous watery diarrhoea may occur, leading rapidly to severe dehydration with 
hypovolaemic shock; 
 for cases with severe dehydration appropriate antibiotics may shorten the duration of 
the illness. 
2. Assessment of the severity of dehydration 
The very first step in the treatment of cholera, as well as of other diarrhoeal diseases, is the 
assessment of the severity of dehydration. The WHO criteria to assess the severity of 
dehydration are based on the evaluation of few simple signs and symptoms (Table 1).  
Look at  
-Conditions a 
-Eyes b 
-Thirst 
 
 Well, alert 
 Normal 
 Drinks normally, not 
thirsty 
 Restless, irritable 
 Sunken 
 Thirsty, drinks 
eagerly 
 Lethargic or unconscious 
 Sunken 
 Drinks poorly, or not 
able to drink 
Fell 
-Skin pinch c 
 
 Goes back quickly   Goes back slowly  Goes back very slowly 
Decide 
No 
Dehydration 
Some 
dehydration 
Severe 
dehydration 
aBeing lethargic and sleepy are not the same. A lethargic child is not simply asleep: the child's mental 
state is dull and the child cannot be fully awakened; the child may appear to be drifting into 
unconsciousness.  
bIn some infants and children, the eyes normally appear somewhat sunken. It is helpful to ask the 
mother if the child's eyes are normal or more sunken than usual.  
cThe skin pinch is less useful in infants or children with marasmus or kwashiorkor, or obese children. 
Other signs may be altered in children with severe malnutrition.  
Table 1. WHO criteria for the assessment of dehydration in patients with diarrhoea 
3. Treatment of dehydration 
The treatment of patients with dehydration due to cholera follows the same guidelines 
given for patients with dehydration due to other diarrhoeal diseases, and is substantially 
consistent among different guidelines (WHO 2011, NICE 2009, WGO 2008, AAP 1996). Here 
are reported the WHO guidelines.  
3.1 How to treat severe dehydration 
Patients who develop the typical clinical picture of cholera with severe diarrhoea and rapid 
fluid loss risk to quickly develop hypovolemic shock, hypoglycemia, coma and seizures and 
are at risk of dying within a few hours of onset. These patients need to be treated with 
intravenous fluids, and need to be monitored very closely. The initial intravenous (IV) 
infusion should be given very rapidly to restore an adequate blood volume, as evidenced by 
normal blood pressure and a strong radial pulse. Typically, an adult weighing 50 kg and 
with severe dehydration would have an estimated fluid deficit of five litres. The first two 
litres should be given within 30 minutes, and the remainder in the following three hours. 
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With cholera, unusually large amounts of oral rehydration salts (ORS) solution may be 
required to replace large continuing losses of watery stool after dehydration is corrected. 
The amount of stool lost is greatest in the first 24 hours of illness, being largest in patients 
who present with severe dehydration. During this period, the average fluid requirement of 
such patients is 200 ml/kg of body weight, but some need 350 ml/kg or more. Patients 
whose stool losses fall in this range, or are higher, usually require intravenous maintenance 
therapy using Ringer's Lactate Solution with added potassium chloride. Additional 
potassium can also be provided by ORS solution as soon as the patient can drink. 
After rehydration, patients should be reassessed for signs of dehydration at least every 1-2 
hours, and more often if there is profuse ongoing diarrhoea. If signs of dehydration reappear, 
ORS solution should be given more rapidly. If patients become tired, vomit frequently or 
develop abdominal distension, ORS solution should be stopped and rehydration should be 
given IV with Ringer's Lactate Solution (50 ml/kg in three hours), with added potassium 
chloride. After this it is usually possible to resume treatment with ORS solution. 
If possible, suspected cholera patients should be treated under observation until diarrhoea 
stops, or is infrequent and of small volume. This is especially important for patients who 
present with severe dehydration. Attention to intake and output is especially important for 
infants. Food should be restarted as soon as deficits are replaced to minimize the nutritional 
impact of the illness; refeeding does not affect purging rates or the duration of diarrhoea.  
The WHO guidelines for treatment of severe dehydration (Table 2) are based on randomised 
controlled trials that have shown that severe dehydration due to diarrhoea can be effectively 
and safety corrected by a rapid infusion over few hours (NICE 2009). Intravenous treatment is 
recommended also in the rare event of ileus or carbohydrate malabsorption. 
3.1.1 What to do if intravenous therapy is not immediately available 
If IV therapy is not available at the facility, but can be given nearby (i.e. within 30 minutes), 
send the patient immediately for IV treatment. If the patient can drink, give the care-taker 
some ORS solution and show her/him how to give it to the patient during the journey. 
If IV therapy is not available nearby, health workers who have been trained can give ORS 
solution by naso-gastric (NG) tube, at a rate of 20 ml/kg body weight per hour for six hours 
(total of 120 ml/kg body weight). If the abdomen becomes swollen, ORS solution should be 
given more slowly until it becomes less distended. If NG treatment is not possible but the 
patient can drink, ORS solution should be given by mouth at a rate of 20ml/kg body weight 
per hour for six hours (total of 120 ml/kg body weight). If the rate is too fast, the patient 
may vomit repeatedly. In this case, the ORS solution must be given more slowly until 
vomiting subsides. Patient receiving NG or oral therapy should be reassessed at least every 
hour. If the signs of dehydration do not improve after three hours, the patient must be taken 
immediately to the nearest facility where IV therapy is available. If neither NG nor oral 
therapy is possible, the patient should be taken immediately to the nearest facility where IV 
or NG therapy is available.  
If rehydration progresses satisfactorily, the patient should be reassessed after six hours and 
a decision on further treatment should made as described above for patients receiving IV 
therapy. 
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 Type of fluid  Quantity  
No 
dehydration 
ORS 
Children<2 years: 50–100 ml, up to 500 mL / day  
Children 2–9 years: 100–200 ml, up to 1000 mL / day 
Patients >9 years: As much as wanted, to 2000 mL / day 
Some 
dehydration 
ORS 
Infants<4 mos (<5 kg): 200–400 mL  
Infants 4–11 mos (5–7.9 kg): 400–600 mL  
Children 1–2 yrs (8–10.9 kg): 600–800 mL  
Children 2–4 yrs (11–15.9 kg): 800–1200 mL  
Children 5–14 yrs (16–29.9 kg): 1200–2200 mL 
Patients >14 yrs (30 kg or more): 2200–4000 mL 
Over 4 hours 
Severe 
dehydration 
Intravenous 
 
Ringer 
Lactate or 
Normal 
saline  
and ORS  
Age < 12 months: 30 mL/kg within 1 hour*, then 70 ml/kg 
over 5 hours 
Age > 1 year: 30 mL/kg within 30 min*, then 70 ml/kg over 2 
and ½ hours 
*Repeat once if radial pulse is still very weak or not detectable  
Indications for monitoring the patient 
 Reassess the patient every 1-2 hours and continue hydrating. If hydration is not 
improving, give the IV drip more rapidly. 200ml/kg or more may be needed during 
the first 24 hours of treatment. 
 During IV rapid infusion the heart rate and the respiratory rate should decrease. If they 
increase, suspect a fluid overload. 
 After 6 hours (infants) or 3 hours (older patients), perform a full reassessment. Switch 
from intravenous to ORS solution if hydration has improved and the patient can drink. 
Table 2. WHO Fluid Replacement Recommendations 
3.1.2 What types of fluids to avoid 
Treating a patient with severe dehydration from infectious diarrhoea with hypotonic 
solutions such as 5% dextrose with 1/4 normal saline is unsafe. Severe dehydration usually 
occurs as a result of bacterial infection (such as cholera), which may lead to greater sodium 
losses in feces (60 to 110 mmol/L). A 1/4 normal saline solution contains sodium (Na) 38.5 
mmol/L, and this does not balance the sodium losses. Intravenous infusion with 5% 
dextrose with 1/4 normal saline will thus lead to severe hyponatremia, convulsion, and loss 
of consciousness. (WGO 2008) 
3.2 How to treat cholera with moderate or mild dehydration  
Patients with cholera but no sign of severe dehydration can be treated with ORS (Table 
2). Interestingly, historical events surrounding cholera epidemics have marked the 
transition to modern rehydration therapy. It was during a cholera epidemic at the time of 
the Bangladesh Liberation War in 1971 that ORS was proven to be an effective treatment 
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for diarrhoea. As medical teams ran out of intravenous fluids to treat the spreading 
cholera epidemic, the staff was instructed to distribute ORS to the 350,000 people in 
refugee camps. Over 3,000 patients with cholera were treated. The death rate was only 
3.6% as opposed to the typical 30% registered with intravenous fluid therapy 
(Bhattacharya et al. 1994). The physiological basis for ORS use lies in the knowledge that 
glucose can enhances sodium and water absorption through the sodium-glucose 
cotransport on intestinal mucosa, even during diarrhoea. Intestinal mucosa is not 
disrupted during cholera. Moreover, ORS can be given by family members instead of 
trained staff thus allowing for large populations to be treated even in emergency 
contexts (Sacks et al. 2004).  
This ecological evidence was confirmed by a Cochrane systematic review of seventeen trials 
in children with gastroenteritis (Hartling et al.2006). The meta-analysis showed no clinically 
significant differences in outcomes between ORS and intravenous rehydration therapy. It’s 
widely accepted that patients presenting with mild to moderate dehydration secondary to 
acute gastroenteritis, including cholera, should initially be treated with ORS. However, it 
must be remembered that mild cases of cholera, if not further investigated, can be 
misdiagnosed for other diarrhoeal diseases, while according to WHO estimates up to 80% of 
people with cholera present only mild diarrhoea. Patients with moderate or mild 
dehydration need to be followed up to ensure that they do not develop severe dehydration. 
The patients and their care-takers need to be instructed to come back and seek care should 
diarrhoea become more severe, or other danger signs appear (inability to drink, weakness 
and deterioration of the neurological state, blood in the faeces).  
3.2.1 Rice based ORS  
Polymer-based ORS contain whole rice (amylopectins), as in rice-based ORS or rice syrups 
(maltodextrins), or other sources of polymers such as wheat, sorghum, and maize (high 
amylase-resistant starch). In these polymer-based solutions, the glucose is slowly released 
after digestion and is absorbed in the small bowel, enhancing the reabsorption of water and 
electrolytes secreted into the bowel lumen during diarrhoea.  
A 1998 Cochrane Review of rice-based ORS for the treatment of diarrhoea concluded that 
rice-based ORS significantly reduce the mean 24 hour stool output in adults and children 
with cholera or cholera-like diarrhoea, but results were inconclusive for infants and children 
with non-cholera diarrhoea (Fontaine et al. , 1998). 
A recent Cochrane review evaluated all polymers (eg rice, wheat, maltodextrins, maize, 
sorghum, or corn)- based ORS for the treatment of diarrhoea (Gregorio et al., 2009).  
 There were fewer unscheduled intravenous infusions in the polymer-based ORS group 
compared with glucose-based ORS (ORS < 310 and < 270 groups combined) (RR 0.75, 
95% CI 0.59 to 0.95; 2235 participants, 19 trials) 
 Adults positive for Vibrio cholerae had a shorter duration of diarrhoea with polymer-based 
ORS than with ORS < 270 (MD -7.11 hours, SD -11.91 to -2.32; 228 participants, 4 trials).  
 Wheat-based ORS resulted in lower total stool output in the first 24 hours compared 
with ORS < 270 (MD-119.85 g/kg, SD -114.73 to -124.97; 129 participants, 2 trials).  
 Adverse effects were similar for polymer-based ORS and glucose-based ORS. 
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WHO and the International Centre for Diarrhoeal Disease research (ICDDR) recommend 
using rice-based ORS in the treatment of cholera. Rice based-ORS may be available in 
packets containing pre-cooked rice powder. Alternatively, uncooked rice powder may be 
added to water, boiled for 5 minutes and allowed to cool before adding salts in the same 
concentration as in ORS (WHO 2004).  
3.2.2 Low osmolarity ORS 
For several decades, the most widely recommended formulation of ORS contained 90 mmol 
of sodium and had a total osmolarity of 311 mOsm/L. However, the amount of salts and 
glucose has always been a subject of debate, and other formulas have been experimented in 
the field (Table 3).  
 
Standard 
ORS 
Reduced Osmolarity ORS
(mEq or mmol/l) 
Glucose 111 111 75-90 75 
Sodium 90 50 60-70 75 
Chloride 80 40 60-70 65 
Potassium 20 20 20 20 
Citrate 10 30 10 10 
Osmolarity 311 251 210-260 245 
Table 3. Composition of standard and reduced osmolarity ORS solutions 
Recently, reduced osmolarity ORS (osmolarity decreased to 245 mOsm/L or lower, reduced 
amount of sodium) have proved to be superior to high osmolarity ORS in treating acute 
diarrhoea (Hahn et al, 2001). Based on the greater efficacy of reduced osmolarity ORS 
solution, especially for children with acute, non-cholera diarrhoea, WHO and UNICEF now 
recommend that countries use and manufacture reduced osmolarity ORS in place of the 
previously recommended standard ORS solution (WHO 2004). However, since cholera is 
associated with significant electrolyte loss especially among children, there are concerns 
about potential adverse effects (i.e. hyponatraemia) of a reduced osmolarity solution in 
people with cholera. A Cochrane review set out to answer these questions (Murphy et al., 
2004). The review included seven randomised controlled studies (RCTs) on adults and 
children with acute cholera (confirmed by stool microscopy or stool culture or presumed to 
be caused by Vibrio cholerae).  
 Five trials (n=616) reported on need for unscheduled intravenous infusion and showed 
no difference between glucose-based reduced osmolarity and standard ORS (RR 
0.86,95% confidence interval 0.66 to 1.12). 
 Four trials (n=465) showed biochemical hyponatraemia was more common with 
glucose-based reduced osmolarity ORS (RR 1.67, 95% CI 1.09 to 2.57), but showed no 
difference in severe biochemical hyponatraemia between the groups (RR 1.58, 95% CI 
0.62 to 4.04). No trials reported symptomatic hyponatraemia.  
In conclusion, in a reasonably large sample of patients with cholera outcomes were similar if 
treated with reduced osmolarity ORS or standard ORS, apart from asymptomatic 
hyponatraemia, which was more common with reduced osmolarity ORS. The conclusion of 
the Cochrane authors is that while it may be easier to administer a single ORS formulation 
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worldwide, the potential harms of, and limited evidence on improved efficacy, of reduced 
osmolarity ORS for patients with cholera should be kept in mind. No further studies have 
been published to date, and so far the conclusion of the Cochrane authors seems reasonable 
(Murphy et al., 2004).  
4. Antimicrobial therapy 
Several trials have proved the benefits of antibiotics in treating cholera. Antibiotics reduce the 
total volume of stool passed, reduce diarrhoea duration, and shorten the period of faecal 
excretion of V. cholerae, thereby reducing cholera transmission. WHO, ICCDR, CDC and 
several other agencies recommend that all cases of suspected cholera with severe dehydration 
should receive an oral antimicrobial known to be effective against strains of Vibrio cholerae in 
the area. WHO guidelines for antibiotic treatment of cholera are reported in Table 4.  
Antibiotic(s) of choice Alternative(s) 
Doxycycline 
Adults: 300 mg once or 
 
Tetracycline 
Children: 12.5 mg/kg  
Adults: 500 mg  
 
4 times a day x 3 days 
Erythromycin 
Children: 12.5 mg/kg  
Adults: 250 mg  
 
4 times a day x 3 days 
All doses shown are for oral administration. If drugs are not available in liquid form for use in young 
children, it may be necessary to use tablets and estimate the doses reported in this table. The first dose 
should be given as soon as vomiting stops, which is usually 4-6 hours after starting rehydration therapy. 
Table 4. WHO guideline of antimicrobial treatment of cholera 
Tetracycline-resistant strains of V. cholerae O1 have appeared in many countries. Alternative 
antimicrobials for treating cholera in children are trimethoprim/sulfamethoxazole (TMP-
SMX) (5 mg/kg TMP + 25 mg/kg SMX, b.i.d. [twice a day] for 3 days), furazolidone (1.25 
mg/kg, q.i.d. [four times a day ] for 3 days), norfloxacin (WGO 2008) and azitromicin (Saha 
et al., 2006, Nelson et al., 2010). The choice of antimicrobial should depend on the known 
resistance/sensitivity pattern of V. cholerae in the region. The information may be available 
from local health institutions. Otherwise, especially in the case of an epidemic, laboratory 
investigations are required. However, it should be noted that severe dehydration leads to 
death in cholera, and only rehydration will prevent death. Antibiotics, while useful, are not 
a lifesaving therapeutic measure, particularly for cholera (ICDDR).  
It has been shown that 20-30% of patients' household contacts develop symptoms of cholera 
within 10-20 days (Wei et al., 2009). The prevention of transmission is based on hygienic 
measures (soap, sanitation, potable water). Chemoprophylaxis for the prevention of 
transmission is debated but not recommended at the moment (Framer et al., 2011). Some 
evidence from past epidemics in Tanzania and Ecuador suggest that chemoprophylaxis may 
lead to increased bacterial resistance, without compensatory gains in survival (Weber et 
al.,1994).  
www.intechopen.com
 
Cholera 
 
210 
5. Zinc  
Zinc deficiency, as well as other micronutrient deficiencies, is wide-spread in low and 
middle income countries and is thought to have importation health consequences, especially 
in children. Zinc influences the activity of over 300 enzymes, controlling different functions 
such as immunity, growth, and development of the nervous system (IZiNCG 2004). There 
are several different mechanism of action of zinc on acute diarrhoea (Berni Canani et al., 
2010). Zinc has a direct effect on ion channels, acting as a potassium-channel blocker of 
adenosine 3-5-cyclic monophosphate-mediated chlorine secretion (Hoque et al., 2009, Hoque 
e tal., 2005). Zinc restores mucosal barrier integrity and enterocyte brush-border enzyme 
activity, and promotes the production of antibodies and circulating lymphocytes against 
intestinal pathogens, including cholera (Alberts et al., 2003):  
A Cochrane review evaluated the efficacy and safety of zinc supplements in the treatment of 
diarrhoea in children (Lazzerini et al., 2008).  
 In acute diarrhoea, zinc shortened the duration of diarrhoea (MD -9.60 h, 95% CI -18.25 
to -0.96 h; 4242 children, 13 trials), with fewer children with diarrhoea by day three (RR 
0.77, 95% CI 0.67 to 0.89; 1568 children, three trials), day five (RR 0.74, 95% CI 0.55 to 
0.99; 1646 children, four trials), and day seven (RR 0.82, 95% CI 0.72 to 0.94; 5528 
children, 10 trials). The benefit of zinc in children over six months was consistent in 
subgroup analysis.  
 In children under six months, no benefit was demonstrated.  
 No trial reported serious adverse events, but vomiting was more common in zinc-
treated children with acute diarrhoea (RR 1.59, 95% 1.27 to 1.99; 5189 children, 10 trials). 
One study evaluated the efficacy of zinc supplements selectively on cholera. The study 
enrolled only children and found a 12% reduction on the duration of diarrhoea compared to 
control patients and 11% less stool output (Roy et al., 2008). 
Since 2004, zinc supplementation (10-20 mg for 10-14 days) is recommended by WHO, 
UNICEF and other agencies for all children with diarrhoea,, including cholera (WHO 2004). 
By continuing zinc supplementation for 10 to 14 days, the zinc lost during diarrhoea is fully 
replaced and the risk of the child having new episodes of diarrhoea in the following 2 to 3 
months is reduced. 
6. Racecadotril  
Racecadotril is an antisecretory drug that inhibits enkephalinase. Enkephalins are 
endogenous opiate substances which act as neurotransmitters, especially along the digestive 
tract. By inhibiting enkephalinase, racecadotril reinforces the physiological activity of 
endogenous enkephalins, which is to elicit intestinal antisecretory activity without affecting 
intestinal transit time or motility.  
To date, only one study has evaluated racecadotril in the treatment of cholera (Alam et al., 
2003). The study is a double blind, randomised, placebo controlled clinical trial involving 
110 adult male cholera patients who received either racecadotril or placebo in addition to 
standard cholera treatment. The major outcome measures (stool output, oral rehydration 
solution (ORS) intake, requirements for unscheduled intravenous fluid infusion, and 
duration of diarrhoea) were compared between the groups. The study demonstrated that 
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racecadotril therapy, although safe, does not provide additional benefit in the treatment of 
severe cholera in adults. 
7. Loperamide  
No clinical study was retrieved on efficacy and safety of loperamide in cholera. WHO 
recommends that cholera antidiarrhoeal medicines, such as loperamide, should not be given 
(WHO 2011). 
8. How to manage a cholera epidemic 
ICCDR is a research centre with vast experience in cholera epidemics. Reported below are 
the ICCDR guidelines on how to manage a cholera epidemic (ICDDR 2004).  
8.1 The risk associated with a cholera epidemic 
Despite the advances made in treatments that can prevent deaths from cholera, a large 
number of patients still die each year, particularly during epidemics. Unlike any other 
diarrhoeal disease, the rate and volume of fluid loss in cholera can threaten life within hours 
of onset. Cholera deaths can only occur either due to lack of treatment or to inadequate 
treatment and can be easily averted by prompt and effective rehydration therapy. Deaths 
are always highest at the beginning of epidemics and are usually associated with areas that 
have communication difficulties. Access to treatment facilities is often the major problem for 
cholera patients requiring medical care, particularly in rural areas, where epidemics of the 
disease are common. It was demonstrated that temporary field treatment centres can be 
effective in averting deaths during cholera epidemics. The overall aim of makeshift 
treatment centre, therefore, is to provide quick access to treatment and thus to ensure 
prevention of deaths. The expected effectiveness of a makeshift treatment centre will 
depend on sound planning and on efficient running of the centre.  
8.2 When is a temporary treatment centre needed? 
There are no rigid rules to follow in deciding when to set up a makeshift treatment centre 
and what the ideal location for such a centre would be. However, experience suggests that a 
temporary treatment centre is usually needed when:  
a. a large number of patients with acute watery diarrhoea accompanied with deaths are 
reported from an area from where transportation to the nearest health facilities is 
difficult;  
b. an epidemic of acute watery diarrhoea involves a large area and is spreading;  
c. natural disasters and diarrhoea outbreak occur simultaneously in many areas, such as 
in post-cyclone epidemics. 
8.3 What would be the best location? 
The specific objective of operating a makeshift treatment centre is to take the emergency 
health care services to the doorstep of patients who would otherwise be at risk of death 
during cholera epidemics. Given the limited resources available, providing door-to-door 
www.intechopen.com
 
Cholera 
 
212 
health care services in such emergencies is difficult. The optimum benefit of a temporary 
treatment centre can, therefore, be derived if the treatment centre is set up at a location, 
which is within easy reach of patients from the affected areas. In rural and remote areas, this 
is sometimes not an easy task. 
Although health posts are ideal for the purpose, they may not be easy to access from the 
affected areas. Therefore, alternatives such as schools or any other available spaces that can 
facilitate access to the centre should be selected. 
8.4 Who should be involved? 
The success of a temporary treatment centre depends on the extent to which the treatment 
facilities are used. Efforts should be made to inform the local population of the physical 
presence of the treatment centre and its location. Community leaders, village practitioners, 
and union council members should be involved. The local community leaders and the union 
council officials are the key persons and should be consulted for providing space for the 
treatment centre, informing the population and organizing community members to run the 
treatment centre. The other important persons are the government employed Health 
Assistants and the village practitioners who are the providers of day-to-day health care at 
village level. Family members of the patients are to provide nursing care and food for the 
patient. 
8.5 Resources needed for a temporary treatment centre 
Once the local health care administrators have decided to set up a treatment centre, the next 
stage is to make plans for the mobilization of resources. While planning to set up a 
makeshift treatment centre it is important to keep in mind that the effectiveness of a 
makeshift treatment centre will depend on establishing the centre quickly and moving the 
logistics easily. One should plan for requirements that are basic and minimum. Due to 
difficulty of access, transportation of large quantity of supplies to the temporary treatment 
centre is difficult. Therefore, arrangements should be made to receive required supplies at 
regular intervals from the permanent source. The basis for estimating resources will depend 
on the expected patient-load for the treatment centre and the duration of the epidemic. To 
do this, one should consider these important points: a) at what stage of the local epidemic 
the treatment centre is to be set up; b) what the magnitude of the epidemic is, in terms of 
area and population affected. This can be assessed by analyzing the information available 
locally. In a cholera endemic area such as Bangladesh, seasonal outbreaks usually last 6-8 
weeks. However, in newly- infected areas, in refugee camps or in the case of disaster-
induced epidemics the period may be longer. The basic and important resources needed are:  
a. personnel,  
b. rehydration fluids,  
c. antibiotics, and  
d. a few other essential items such as butterfly needles, etc. 
8.5.1 Personnel, drugs, and supplies needed for a temporary treatment centre 
Experience has shown that during diarrhoea epidemics in rural areas, 10-20 persons per 
1000 population may complain of diarrhoea and most of them may have cholera infection. 
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Many patients with less severe diarrhoea tend to remain at home. Usually 10% to 20% of the 
patients who seek treatment at the health facilities during epidemics may have severe 
dehydration. Between 150 and 200 patients may seek treatment in a temporary treatment 
centre that covers up to two unions (approx. pop. 40,000). Nearly half of the diarrhoea cases 
seeking treatment don’t show signs of dehydration. Between 25% and 30% of the cases, 
however, may show signs of some dehydration and can be, to a large extent, treated with 
ORS. Approximately, 15% to 20% of the cases may need treatment for severe dehydration. 
They will be needing initial rehydration therapy with IV fluids. Resource requirements were 
estimated on the basis of a temporary treatment centre expecting to handle at least 100 
diarrhoea patients during an epidemic. 
8.6 Assessment of the magnitude and spread of epidemic 
Assessment of the magnitude of epidemic, particularly with relation to the number of 
persons affected and the geographic distribution of the epidemic is important for planning 
and for operating the temporary treatment centre. A temporary treatment centre will be less 
useful if patients fail to use it and when the epidemic moves away from the catchment area. 
It has been seen that many cholera patients remain at home during epidemics because of the 
difficulty to access the health facilities or due to milder forms of disease, which escape 
attention. Many of these patients are inadequately treated or not treated at all. Organizing a 
local surveillance system to identify cholera patients and to monitor the course of the 
epidemic is, therefore, essential. 
Objectives of the epidemic surveillance:  
 Identify cholera patients 
 Provide quick treatment 
 Assess the magnitude of the epidemic 
 Assess the adequacy of available stock of essential supplies 
 Identify the pathogen involved and its drug sensitivity patterns 
 Set up control measures and monitor progress. 
Type of information needed: 
 Who are affected and where they are  
 Which are the organisms causing the epidemic 
 What is the drug sensitivity patterns of the organisms 
Source of information: 
 Local public health establishments 
 Permanent treatment facilities 
 Local field health staff 
 Private health care providers 
 Available records of laboratory investigations 
 Community leaders 
Box 1. Epidemic surveillance of cholera  
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8.6.1 Identify cholera cases 
One common problem with cholera surveillance is the case definition. The clinical 
manifestations of cholera cases vary widely. Nevertheless, the use of a standard case 
definition can facilitate detection of suspect cases. The following definition will assist the 
field workers to identify cases:  
 A patient who is above 2 years of age, suffering from acute watery diarrhoea with rice 
watery stool, with or without vomiting and with signs of dehydration, should be 
suspected as a case of cholera during a cholera outbreak.  
However, it is still difficult to predict an epidemic and to detect it early in its course because 
epidemics usually start abruptly, and affect many people within days. Furthermore, the 
inadequacy of laboratory diagnostic facilities and information systems contributes to 
delaying both detection and response. Useful indicators for suspecting an outbreak of 
cholera are: 1) incidence of adult death due to watery diarrhoeal illness of short duration, or 
2) increase in hospitalization rates due to acute watery diarrhoea with or without vomiting, 
particularly in individuals over 2 years of age. 
8.6.2 Collecting illness information 
Information on age, gender, location of the patient, onset of diarrhoea, dehydration status, 
diagnosis, and treatment administered, should be collected and recorded on a simple form. 
Information relating to other cases and deaths in the family or in the neighbourhood should 
also be collected. The mapping of the location of cases is important for the identification of 
the affected areas and of the source of infection and to monitor the course and spread of the 
epidemic. 
8.6.3 Laboratory identification of organisms causing an outbreak 
The identification of Vibrio cholerae and their drug sensitivity patterns can only be 
established by laboratory methods. Laboratory analysis of specimens from suspected 
cases are, therefore, essential for establishing the cause of an outbreak. However, 
laboratory tests are expensive. During a suspected cholera epidemic, isolation of V. 
cholerae from a sample of patients’ specimens can contribute to establishing the cause of 
the epidemic. A sample of specimens (Rectal swabs) collected in Carry-Blair medium 
should be sent to the nearest reference laboratory for culture and to determine antibiotic 
sensitivity patterns. Furthermore, results of antibiotic sensitivity and resistance patterns 
from different regions of the country will be useful for the formulation of standard drug 
protocols. Before collecting rectal swabs one should make sure that the patient did not 
receive any antibiotics. 
8.7 Control and prevention of local spread of an epidemic  
8.7.1 Disposal of wastes and disinfecting contaminated material  
It is virtually impossible to provide patients with regular hospital beds in a temporary 
treatment centre. Contamination of cholera patient surroundings is therefore unavoidable. 
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Bedding, including mats, can be disinfected by thorough drying in the sun. After drying, all 
soiled and contaminated materials should be washed with detergents. A pit-hole in the 
ground for draining the water used for washing can minimize chances of further 
contamination. Bleaching powder should be used to disinfect the pit. The pit can also be 
used to dispose of cholera stool. The floor of the treatment centre can be disinfected by 
washing, swabbing or sprinkling with bleaching powder solution. Attendants should be 
advised to wash their hands and clothes thoroughly with detergents. 
8.7.2 Water 
Drinking safe water is a basic requirement. Tubewell water for drinking and for domestic 
use, if available, should be encouraged. Boiling of water makes it safer. Stored water can 
also be easily contaminated. Use of narrow-necked itchers for water storage greatly 
reduces the risk of contamination. Use of bleaching powder solution can disinfect 
contaminated water. The risk of infection can be further reduced by washing hands with 
soap and water after defecation and before handling or eating food. Ponds receiving 
drainage from latrines should not be used to wash utensils or for bathing. Washing stool-
contaminated clothes and bedding of diarrhoea patients can contaminate the surface 
water (ponds) used for domestic purpose. Drying these materials in the sun before 
washing can reduce the risk of contamination. Potentially contaminated water can be 
disinfected with 6 mL of bleaching powder solution per 10 L of water (33 g of bleaching 
powder dissolved in one litre of water makes the stock solution). Treated water should be 
left to sit for at least 30 minutes before use. 
8.7.3 Food 
Many raw foods, such as fish and vegetables, are contaminated with cholera bacteria. Raw 
food should not be eaten. All foods should be well-cooked and kept covered. Left-overs 
should be thoroughly re-heated and stale food should be discarded. Food should be eaten as 
soon as it is cooked or while still hot. 
8.7.4 Washing hands 
Washing hands with water and soap after defecation, before preparing, serving and eating 
food will reduce the chances of getting infected with the cholera bacteria. 
8.7.5 Health education 
Simple health education messages include: eat freshly cooked food; reheat leftovers and eat 
while still hot; drink tubewell water or boiled water; wash utensils in clean water and dry 
them in the sun; wash hands before handling or eating food and after defecation. 
9. Conclusions 
The effective management of cholera is based on few simple rules and procedures, 
summarized in Box 2.  
www.intechopen.com
 
Cholera 
 
216 
1. Assess the severity of dehydration. 
 
2. Replace fluids: 
 severe dehydration: IV infusion, replace 10% of the body weight within 3–6 hr. 
 moderate or mild dehydration: standard ORS, rice-based ORS if possible. 
 
3. Monitor the patient:  
 repeate the evaluation of the severity of dehydration 
 monitor stool output (use cholera cot if possible). 
 
4. Maintain hydration:  
 replace continuing fluid losses until diarrhoea stops. 
 
5. Give an oral antibiotic to dehydrated patients as soon as vomiting stops. 
 based on the local known resistance/sensitivity pattern 
 
6. Provide food as soon as patient is able to eat (within a few hours). 
 
7. Recognize complications such as hyponatriemia. 
 
8. Give to children zinc supplementation  
 dose 10-20 mg for 10-14 days  
 
9. In case of cholera epidemic:  
 Aggressive case finding and efficient transport. 
 Set up treatment centres for remote areas. 
 Start epidemic surveillance. 
 Strengthen control and prevention measures.  
Box 2. Synthesis of recommendations for the management of cholera  
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